Spruce Biosciences Inc (SPRB)

[Triple nickle]

One day rsi crosses value 48 and it’s 2.52 plus

[TheFinalCD]

3.38-2.54 1st 15m red candle

whats next?

[TheFinalCD]

ok Ralphie boy....LOL

[subslover]

To Pluto and beyond Captain video

[TheFinalCD]

$SPRB ZOOM 2.85-3.25

[subslover]

Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan
January 05 2023 - 04:00PM
Business Wire
Alert
Print
Share On Facebook
Partnership aims to accelerate global development and commercialization plans for tildacerfont to address worldwide unmet medical need in congenital adrenal hyperplasia (CAH)

Deal advances strategy to partner tildacerfont commercial rights outside the United States

Spruce to receive $15 million upfront payment plus development and commercial milestone payments in addition to tiered double-digit royalties on net sales in Japan

Spruce Biosciences, Inc. (Nasdaq: SPRB) and Kaken Pharmaceutical Co. Ltd (Tokyo Stock Exchange: 4521) today announced that the companies have entered into an exclusive licensing agreement for the development and commercialization of Spruce’s product candidate, tildacerfont, for the treatment of congenial adrenal hyperplasia (CAH) in Japan.

Under the terms of the agreement, Spruce will receive an upfront payment of $15 million from Kaken and will be eligible to receive additional payments upon the achievement of future development and commercial milestones, as well as tiered double-digit royalties on net sales in Japan. Kaken will be responsible for the clinical development and commercialization of tildacerfont in Japan, and Spruce will retain all rights to tildacerfont in all other geographies. As part of the agreement, Kaken will have the first right of negotiation to expand the scope of the agreement to include China (including Hong Kong, Taiwan, and Macau), South Korea and other specified Southeastern Asian (ASEAN) countries. Kaken will also be responsible for securing and maintaining regulatory approvals necessary to market and sell tildacerfont in Japan.

“We are excited to enter into this strategic partnership with Kaken Pharmaceutical designed to accelerate our global development plans and bring tildacerfont to patients in Japan who suffer from CAH,” said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences. “As a specialty pharmaceutical company with a strong presence in Japan, Kaken is the ideal strategic partner for the territory, and supports Spruce’s partnering strategy to develop tildacerfont in markets outside of the United States. We believe Kaken’s track record of development and commercialization in the Asia-Pacific region will be instrumental in delivering the full therapeutic potential of tildacerfont and bringing a new treatment option to CAH patients in Japan, if approved.”

“We are pleased to begin a collaboration with Spruce, a company committed to transforming the lives of patients with CAH,” said Hiroyuki Horiuchi, President and Representative Director of Kaken. “Through this collaboration, we hope we can contribute to CAH patients and their families, who currently have limited available treatment options in Japan.”

About Tildacerfont

Tildacerfont is a potent and highly selective, non-steroidal, oral antagonist of the corticotropin-releasing factor (CRF) 1 receptor. The CRF1 receptor is abundantly expressed in the pituitary gland where it is the primary regulator of the hypothalamic-pituitary-adrenal (HPA) axis. By antagonizing the CRF1 receptor, tildacerfont has the potential to address the uncontrolled cortisol feedback regulatory pathway in CAH, and in turn reduce the production of adrenocorticotropic hormone (ACTH) in the pituitary, limiting the amount of androgen produced downstream from the adrenal gland. Tildacerfont has been evaluated in 235 patients across eight clinical trials in which it has been generally well tolerated. No drug-related serious adverse events have been reported across completed clinical trials. Tildacerfont is currently being evaluated in clinical trials for adult classic CAH, pediatric classic CAH, and polycystic ovary syndrome.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow Spruce on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube.

About Kaken Pharmaceutical

Kaken Pharmaceutical is a specialty pharmaceutical company in Japan with strong experience in developing and commercializing novel pharmaceuticals in the fields of orthopedics and dermatology. Kaken concentrates its R

[Awl416]

Moving

[TheFinalCD]

5.61 pre market

Message in reply to:

waiting for solid 5$ break

[ming1234]

waiting for solid 5$ break

[chemist72]

Think its called "day trading".

When you see a stock with such a low float trading millions and millions of shares, you can bet there are a lot of folks day trading the crap out of this stock.

I just sit back and watch the show with my small shares.

[Roadtojourney]

So much manipulation here??

[europtiger]

5 break today

[da_stock_analyst]

HOT stocks! #SOPA ?? #SEAC ?? #SPRB ?? Technical analysis and price targets

[TheFinalCD]

good job holding SPRB hit over $5 in ah session

[europtiger]

Weeeee…. But back down again lol

But this will develop well imo

[TheFinalCD]

4 break

[europtiger]

Let’s see how she develops today

[Wayne R]

Interesting. The stock rarely trades, you create a thread the VERY SAME DAY that the stock has massive volume with no news.

The SEC watches this kind of stuff like I do. Very easy to find.

As of September 30, 2021, the Company had an accumulated deficit of $93.9 million and does not expect positive cash flows from operations in the foreseeable future. The Company has funded its operations primarily through the issuance and sale of equity securities and debt.

The company probably thanks you for letting them fund their operations. I imagine they were very busy Friday, not with their business, but selling shares.


What a windfall, a bunch of knuckleheads on some innernut stock sites make a massive Friday pump.


Were you paid by them? or paid by a third party?

[crudeoil24]

I bought a few earlier before lunch! Holding for more upside next week. Go SPRB.

[Sonic Boom]

Nice day here

[europtiger]

We are close… I sold half hold rest over weekend

[Jess070283]

What a lovely bounce. Not selling any until $5+!

[Sonic Boom]

Nice day today, glad I loaded up.$SPRB

[europtiger]

Got me some 2,80,s lol

[europtiger]

To Mans bullstraps the Last des weeks… all the best to you

[Jess070283]

Load it up! $5+

[europtiger]

Ok thx

[crudeoil24]

No, covid is interfering in enrollment status of clinical trials.

[europtiger]

Hey there co24,how things? You buying in here?

[crudeoil24]

PT > $15.00 > Oppenheimer analyst Hartaj Singh initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Outperform rating and announces Price Target of $15.

[crudeoil24]

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for rare endocrine disorders. The Company's development product candidate, tildacerfont, is a non-steroidal therapy that offers disease control for patients suffering from congenital adrenal hyperplasia (CAH). Tildacerfont is a potent and selective, non-steroidal, oral, small-molecule antagonist of the corticotropin-releasing hormone receptor 1 (CRF1) receptor, which is a regulator of the production of adrenocorticotropic hormone (ACTH). Its CAHmelia-203, is a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with CAH with poor disease control. Its CAHmelia-204, is a second Phase IIb clinical trial in adult patients with CAH with good disease control focused on glucocorticoid reduction. It has also conducted two Phase IIa clinical trials of tildacerfont in adult patients with CAH on stable glucocorticoid therapy.